SIGA Technologies (OTCMKTS: SIGA) and Trillium Therapeutics (NASDAQ:TRIL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares SIGA Technologies and Trillium Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
SIGA Technologies -201.85% N/A -23.22%
Trillium Therapeutics N/A -248.39% -65.21%

Institutional & Insider Ownership

6.7% of SIGA Technologies shares are owned by institutional investors. Comparatively, 45.5% of Trillium Therapeutics shares are owned by institutional investors. 4.7% of SIGA Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares SIGA Technologies and Trillium Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
SIGA Technologies $14.99 million 26.11 -$39.69 million ($0.53) -9.36
Trillium Therapeutics N/A N/A -$23.96 million ($2.57) -3.13

Trillium Therapeutics has lower revenue, but higher earnings than SIGA Technologies. SIGA Technologies is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

SIGA Technologies has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Trillium Therapeutics has a beta of 13.72, meaning that its stock price is 1,272% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for SIGA Technologies and Trillium Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SIGA Technologies 0 0 0 0 N/A
Trillium Therapeutics 0 0 3 0 3.00

Trillium Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 73.91%. Given Trillium Therapeutics’ higher possible upside, analysts clearly believe Trillium Therapeutics is more favorable than SIGA Technologies.

Summary

Trillium Therapeutics beats SIGA Technologies on 7 of the 12 factors compared between the two stocks.

SIGA Technologies Company Profile

SIGA Technologies, Inc. is engaged in the development and commercialization of solutions for various unmet medical needs and biothreats. The Company’s lead product is TPOXX, an orally administered antiviral drug that targets orthopoxviruses infections. TPOXX is a small-molecule drug delivered to the Strategic Stockpile under the Project BioShield Act of 2004 (Project BioShield). TPOXX is an investigational product that is not approved by the United States Food and Drug Administration (FDA) as a treatment of smallpox or any other indication. The Company relies on and uses third parties known as contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company identified a lead pre-clinical drug candidate with activity against four serotypes of the virus and which has shown efficacy in a murine model of disease.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Receive News & Ratings for SIGA Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SIGA Technologies and related companies with Analyst Ratings Network's FREE daily email newsletter.